论文部分内容阅读
一项新的大型独立性试验发现,礼莱公司的选择性雌激素受体调节剂雷洛昔芬(raloxifene,Evista)在预防侵入性乳癌方面与他莫昔芬有相同的疗效,但少有他莫西芬所出现的罕见但严重的不良反应。STAR试验共纳入19 000多例患者,是比较雷洛昔芬与他莫昔芬预防乳腺癌发生效果的最大
A new large-scale independent trial found that Raleigh’s selective estrogen receptor modulator raloxifene (Evista) had the same effect as tamoxifen in preventing invasive breast cancer, but few Rare but serious side effects of tamoxifen. The STAR trial enrolled more than 19 000 patients and compared the greatest effect of raloxifene with tamoxifen in preventing breast cancer